Santen Pharmaceutical Co.... (SNPHY)
Santen Pharmaceutical Statistics
Share Statistics
Santen Pharmaceutical has 351.75M shares outstanding. The number of shares has increased by -11.09% in one year.
| Shares Outstanding | 351.75M |
| Shares Change (YoY) | -11.09% |
| Shares Change (QoQ) | -4.1% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 334.66M |
| Failed to Deliver (FTD) Shares | 3.46K |
| FTD / Avg. Volume | 51.11% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 19.57 and the forward PE ratio is null. Santen Pharmaceutical's PEG ratio is -0.07.
| PE Ratio | 19.57 |
| Forward PE | n/a |
| PS Ratio | 1.73 |
| Forward PS | n/a |
| PB Ratio | 1.7 |
| P/FCF Ratio | 8.41 |
| PEG Ratio | -0.07 |
Enterprise Valuation
Santen Pharmaceutical has an Enterprise Value (EV) of 461.88B.
| EV / Sales | 1.53 |
| EV / EBITDA | 9.11 |
| EV / EBIT | 6.36 |
| EV / FCF | 7.45 |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.54 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 0.57 |
| Interest Coverage | 14.47 |
Financial Efficiency
Return on Equity is 8.7% and Return on Invested Capital is 10.05%.
| Return on Equity | 8.7% |
| Return on Assets | 6.11% |
| Return on Invested Capital | 10.05% |
| Revenue Per Employee | $80.65M |
| Profits Per Employee | $7.12M |
| Employee Count | 3,744 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.85 |
Taxes
| Income Tax | 3.17B |
| Effective Tax Rate | 10.61% |
Stock Price Statistics
The stock price has increased by 4.72% in the last 52 weeks. The beta is 0.2, so Santen Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.2 |
| 52-Week Price Change | 4.72% |
| 50-Day Moving Average | 9.62 |
| 200-Day Moving Average | 10.82 |
| Relative Strength Index (RSI) | 60.58 |
| Average Volume (20 Days) | 6.77K |
Income Statement
In the last 12 months, Santen Pharmaceutical had revenue of 301.96B and earned 26.64B in profits. Earnings per share was 72.62.
| Revenue | 301.96B |
| Gross Profit | 178.71B |
| Operating Income | 38.54B |
| Net Income | 26.64B |
| EBITDA | 50.72B |
| EBIT | 32.54B |
| Earnings Per Share (EPS) | 72.62 |
Balance Sheet
The company has 94.58B in cash and 35.16B in debt, giving a net cash position of 59.42B.
| Cash & Cash Equivalents | 94.58B |
| Total Debt | 35.16B |
| Net Cash | 59.42B |
| Retained Earnings | 240.03B |
| Total Assets | 434.16B |
| Working Capital | 143.97B |
Cash Flow
In the last 12 months, operating cash flow was 72.65B and capital expenditures -10.69B, giving a free cash flow of 61.96B.
| Operating Cash Flow | 72.65B |
| Capital Expenditures | -10.69B |
| Free Cash Flow | 61.96B |
| FCF Per Share | 168.88 |
Margins
Gross margin is 59.18%, with operating and profit margins of 12.76% and 8.82%.
| Gross Margin | 59.18% |
| Operating Margin | 12.76% |
| Pretax Margin | 9.89% |
| Profit Margin | 8.82% |
| EBITDA Margin | 16.8% |
| EBIT Margin | 12.76% |
| FCF Margin | 20.52% |
Dividends & Yields
SNPHY pays an annual dividend of $0.24, which amounts to a dividend yield of 1.7%.
| Dividend Per Share | $0.24 |
| Dividend Yield | 1.7% |
| Dividend Growth (YoY) | -3.8% |
| Payout Ratio | 43.76% |
| Earnings Yield | 5.11% |
| FCF Yield | 11.89% |
Analyst Forecast
Currently there are no analyst rating for SNPHY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 2, 2015. It was a forward split with a ratio of 2499:1000.
| Last Split Date | Apr 2, 2015 |
| Split Type | forward |
| Split Ratio | 2499:1000 |
Scores
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 6 |